



**Amendments to the Claims**

1. (Previously Presented) A compound represented by the structure of formula 1:



wherein R is a residue of a hydroxamic acid derivative histone deacetylase inhibitor; and R<sub>a</sub> is represented by the structure:




wherein R<sub>b</sub> is a hydrogen or an unsubstituted or substituted ethyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, alkynyl, naphthyl, cycloalkyl, heterocycl, heteroaryl, alkylaryl, alkylcycloalkyl, alkylheterocycl, alkylheteroaryl or an amino acid residue; R<sub>c</sub> is a hydrogen or an unsubstituted or substituted alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycl, heteroaryl, alkylaryl, alkylcycloalkyl, alkylheterocycl, alkylheteroaryl or an amino acid residue and

R<sub>d</sub> is hydrogen or an amino protecting group;

or a pharmaceutically acceptable salt thereof.


2. (Previously Presented) The compound according to claim 1, wherein R<sub>b</sub> is a hydrogen, ethyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, benzyl, alkylphenyl, naphthyl or pyridyl; R<sub>c</sub> is a hydrogen, methyl, ethyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, phenyl, benzyl, alkylphenyl, naphthyl or pyridyl.

3. (Previously Presented) The compound according to claim 1, wherein R<sub>a</sub> is selected from the group consisting of:




and wherein  $m$  is an integer of 1 to 10.

4. (Previously Presented) A compound represented by the structure:




wherein each of  $\text{R}_1$  and  $\text{R}_2$  are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkylcycloalkyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyloxy, aryloxy, or pyridine group, or  $\text{R}_1$  and  $\text{R}_2$  are bonded together to form a nitrogen containing heterocyclic ring optionally containing one or more additional heteroatoms, and  $n$  is an integer of 4 to 8;

$\text{R}_3$  is represented by the structure:




wherein  $\text{R}_b$  and  $\text{R}_c$  are independently of each other a hydrogen or an unsubstituted or substituted alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, alkylaryl, alkylcycloalkyl, alkylheterocyclyl, alkylheteroaryl or an amino acid residue; and  $\text{R}_d$  is hydrogen or an amino protecting group.

5. (Previously Presented) The compound according to claim 4, represented by the structure:




wherein n is an integer of 4 to 8.

6. (Previously Presented) The compound according to claim 5, represented by the structure:



$\text{R}_a$  is selected from the group consisting of:




and wherein m is an integer of 1 to 10.


7. Cancelled.

8. Cancelled.

9. (Previously Presented) The compound according to claim 1, represented by the structure:




10. (Previously Presented) The compound according to claim 1, represented by the structure:



(11)


wherein R<sub>1</sub> is a substituted or unsubstituted phenyl, piperidino, thiazolyl, 2-pyridinyl, 3-pyridinyl or 4-pyridinyl and n is an integer of 4 to 8.

11. (Previously Presented) The compound according to claim 1, represented by the structure:




wherein R<sub>1</sub> is a substituted or unsubstituted phenyl, piperidino, thiazolyl, 2-pyridinyl, 3-pyridinyl or 4-pyridinyl and n is an integer of 4 to 8.

12. (Previously Presented) The compound according to claim 1, represented by the structure:




wherein A is an amide moiety, R<sub>1</sub> and R<sub>2</sub> are each selected from substituted or unsubstituted aryl, arylalkyl, naphthyl, cycloalkyl, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amino, thiazoleamino, hydroxyl, branched or unbranched alkyl, alkenyl, alkyloxy, aryloxy, arylalkyloxy, pyridyl, quinolinyl or isoquinolinyl; and n is an integer of 3 to 10.


13. (Previously Presented) The compound according to claim 12, represented by the structure:



14. (Previously Presented) The compound according to claim 12, represented by the structure:




15. (Previously Presented) The compound according to claim 1, represented by the structure:




wherein A is an amide moiety, R<sub>1</sub> and R<sub>2</sub> are each selected from substituted or unsubstituted aryl, arylalkyl, naphthyl, cycloalkyl, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amino, thiazoleamino, hydroxyl, branched or unbranched alkyl, alkenyl, alkoxy, aryloxy, arylalkyloxy, pyridyl, quinolinyl or isoquinolinyl; R<sub>3</sub> is hydrogen, a halogen, a phenyl or a cycloalkyl moiety and n is an integer of 3 to 10.

16. (Previously Presented) The compound according to claim 15, represented by the structure:




17. (Previously Presented) The compound according to claim 15, represented by the structure:



(14b)

wherein  $n$  is an integer from about 3 to 10.


18. (Previously Presented) The compound according to claim 1, represented by the structure:




-wherein L is a linker selected from the group consisting of an amide moiety, O-, -S-, -NH-, NR, -CH<sub>2</sub>-, -(CH<sub>2</sub>)<sub>p</sub>, -(CH=CH)-, phenylene, cycloalkylene, or any combination thereof wherein R is a substituted or unsubstituted C<sub>1</sub>-C<sub>5</sub>alkyl; and wherein each of R<sub>1</sub> and R<sub>2</sub> are independently a substituted or unsubstituted aryl, arylalkyl, naphthyl, cycloalkyl, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amino, thiazoleamino, hydroxyl, branched or unbranched alkyl, alkenyl, alkyloxy, aryloxy, arylalkyloxy, pyridyl, quinolinyl or isoquinolinyl; p is an integer of 0 to 10.

19. Cancelled.

20. (Previously Presented) The compound according to claim 18, represented by the structure:



21. (Previously Presented) The compound according to claim 1, represented by the structure:



(29)

wherein


n is 2, 3, 4, 5, 6, 7 or 8;

q is 0 or 1;

 $\text{p}_1$  and  $\text{p}_2$  are independently of each other 0 or 1;

$\text{R}_1$  and  $\text{R}_2$  are independently of each other an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl or alkylheterocyclyl; or when  $\text{p}_1$  and  $\text{p}_2$  are both 0,  $\text{R}_1$  and  $\text{R}_2$  together with the  $-\text{CH}_2-\text{N}-\text{CH}_2-$  group to which they are attached can also represent a nitrogen-containing heterocyclic ring; or when at least one of  $\text{p}_1$  or  $\text{p}_2$  is not 0,  $\text{R}_1$  or  $\text{R}_2$  or both can also represent hydrogen or alkyl.

22. (Previously Presented) The compound according to claim 1, represented by the structure:




(30)

wherein

n is 2, 3, 4, 5, 6, 7 or 8;

$\text{R}_1$  and  $\text{R}_2$  are independently of each other a hydrogen or an unsubstituted or substituted alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl or alkylheterocyclyl.

23. (Previously Presented) The compound according to claim 1, represented by the structure:




(31)

wherein

n is 2, 3, 4, 5, 6, 7 or 8;

R<sub>1</sub> and R<sub>2</sub> are independently of each other a hydrogen or an unsubstituted or substituted alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl or alkylheterocyclyl.

24. (Previously Presented) The compound according to claim 1, represented by the structure:




(32)

wherein

n is 2, 3, 4, 5, 6, 7 or 8;

R<sub>1</sub> and R<sub>2</sub> are independently of each other an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl or alkylheterocyclyl; or R<sub>1</sub> and R<sub>2</sub> together with the -CH<sub>2</sub>-N-CH<sub>2</sub>- group to which they are attached can also represent a nitrogen-containing heterocyclic ring.

25. (Previously Presented) The compound according to claim 1, represented by the structure:



(33)


wherein

n is 2, 3, 4, 5, 6, 7 or 8;


R<sub>1</sub> and R<sub>2</sub> are independently of each other an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl or

alkylheterocycl; or R<sub>1</sub> and R<sub>2</sub> together with the -CH<sub>2</sub>-N-CH<sub>2</sub>- group to which they are attached can also represent a nitrogen-containing heterocyclic ring.

26. (Previously Presented) The compound according to claim 1, represented by the structure:




wherein A is alkyl, aryl or a group selected from



l, p and q are independently of each other 0, 1 or 2.


27. (Previously Presented) The compound according to claim 1, represented by the structure:



(36)


wherein

A is alkyl, aryl or a group selected from:



wherein R<sub>1</sub>-R<sub>16</sub> are independently of each other a hydrogen or an unsubstituted or substituted alkyl, aryl, cycloalkyl, heterocyclyl, alkylaryl, alkylcycloalkyl or alkylheterocyclyl; or one or more of R<sub>1</sub> and R<sub>2</sub>, R<sub>6</sub> and R<sub>7</sub>, and R<sub>11</sub> and R<sub>12</sub>, together with the nitrogen atom to which they are attached, form a nitrogen-containing heterocyclic ring;

B is



n is 0 or 1; and

l, p and q are independently of each other 0, 1 or 2.

28. (Previously Presented) A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

29. Cancelled.


30. Cancelled.

31. Cancelled.

32. Cancelled.


33. (Previously Presented) The compound of claim 4 selected from the group consisting of:  
Octanedioic acid phenylamide (7-phenylcarbamoyl-heptanoyloxy)-amide;  
Octanedioic acid acetoxy-amide phenylamide;  
Octanedioic acid (biphenyl-4-carbonyloxy)-amide phenylamide;  
Octanedioic acid benzoyloxy-amide phenylamide;  
Octanedioic acid (naphthalene-2-carbonyloxy)-amide phenylamide;  
Octanedioic acid (naphthalene-1-carbonyloxy)-amide phenylamide;  
Octanedioic acid (3-methoxy-benzoyloxy)-amide phenylamide;  
Octanedioic acid (4-methoxy-benzoyloxy)-amide phenylamide;  
Octanedioic acid (2-methoxy-benzoyloxy)-amide phenylamide;  
Octanedioic acid (4-methyl-benzoyloxy)-amide phenylamide;  
Octanedioic acid (4-chloro-benzoyloxy)-amide phenylamide;  
Octanedioic acid (3-phenyl-acryloyloxy)-amide phenylamide;  
Octanedioic acid phenylamide (pyridine-3-carbonyloxy)-amide;  
Octanedioic acid (4-butyl-benzoyloxy)-amide phenylamide;  
Octanedioic acid phenylamide (3-phenyl-propionyloxy)-amide;  
Octanedioic acid phenylamide (4-phenyl-butyryloxy)-amide;  
[1-Benzyl-2-oxo-2-(7-phenylcarbamoyl-heptanoylaminoxy)-ethyl]-carbamic acid benzyl ester;  
and  
[1-Benzyl-2-oxo-2-(7-phenylcarbamoyl-heptanoylaminoxy)-ethyl]-carbamic acid tert-butyl ester;  
Or a stereoisomer thereof;  
Or a pharmaceutically acceptable salt thereof;  
Or a pharmaceutically acceptable salt of the stereoisomer thereof.

34. (Previously Presented) The compound of claim 4 that is



or a pharmaceutically acceptable salt thereof.

35. (Previously Presented) The compound of claim 4 that is



or a pharmaceutically acceptable salt thereof.

36. (Previously Presented) A pharmaceutical composition comprising the compound of claim 33 and a pharmaceutically acceptable carrier.

37. Cancelled.

38. (Previously Presented) The compound according to claim 5, wherein R<sub>b</sub> is a hydrogen, methyl, ethyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, phenyl, benzyl, alkylphenyl, naphthyl or pyridyl;

R<sub>c</sub> is a hydrogen, methyl, ethyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, phenyl, benzyl, alkylphenyl, naphthyl or pyridyl.